Testing new medications for treating substance use disorders
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
This study is looking for people with opioid or cocaine use disorders to try out a new medication called lorcaserin, which might help reduce cravings when combined with another treatment, to see if it can make recovery easier and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10767775 on NIH RePORTER |
What this research studies
This research focuses on early clinical trials to evaluate new pharmacotherapies for substance use disorders, particularly opioid and cocaine use disorders. The team at Virginia Commonwealth University uses a combination of preclinical models and phase I studies to assess the safety and effectiveness of medications like lorcaserin, which has shown promise in reducing substance use in animal models. Patients may participate in trials that explore the effects of lorcaserin in combination with buprenorphine, aiming to improve treatment outcomes for those struggling with addiction.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals diagnosed with opioid or cocaine use disorders, particularly those who may benefit from new treatment combinations.
Not a fit: Patients who do not have substance use disorders or those who are not seeking treatment for addiction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for individuals with substance use disorders.
How similar studies have performed: Previous research has shown promise in using similar pharmacological approaches for treating substance use disorders, indicating potential for success in this area.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Moeller, Frederick Gerard — Virginia Commonwealth University
- Study coordinator: Moeller, Frederick Gerard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.